DelveInsight’s, “Scleroderma Pipeline Insight 2025” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Scleroderma pipeline landscape. It covers the Scleroderma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Scleroderma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Scleroderma Pipeline. Dive into DelveInsight’s comprehensive report today! @ https://www.delveinsight.com/sample-request/scleroderma-pipeline-insight

Key Takeaways from the Scleroderma Pipeline Report

• On January 27, 2026- Tongji Hospital announced a study of Systemic Sclerosis (Ssc) is a rare, systemic autoimmune disease characterized by skin fibrosis and vasculopathy. In addition to the skin, it is a heterogeneous disease that affects multiple organs, including the musculoskeletal, cardiac, pulmonary, and gastrointestinal systems. Patients may experience many symptoms such as pain, fatigue, dyspnea, impaired hand function, dry mouth, and difficulty sleeping. As a result of these symptoms, these patients may experience a decrease in activities of daily living, physical activity level and quality of life, while psychological problems such as anxiety and depression may increase.
• On January 21, 2026- Boehringer Ingelheim initiated a study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype called diffuse cutaneous systemic sclerosis. People with another subtype called limited cutaneous systemic sclerosis can also participate if they are anti Scl-70 antibody positive. Systemic sclerosis is also called scleroderma.
• DelveInsight’s Scleroderma pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Scleroderma treatment.
• The leading Scleroderma Companies such as AstraZeneca, Mitsubishi Tanabe Pharma Corporation, GlaxoSmithKline, Boehringer Ingelheim, Novartis Pharmaceuticals, Certa Therapeutics, Argenx, Cumberland Pharmaceuticals, Sanofi, Amgen, Genentech, Inc., Cabaletta Bio, Kyverna Therapeutics, ChemomAb Ltd., Corvus Pharmaceuticals, Quoin Pharmaceuticals Ltd., aTyr Pharma, APIE Therapeutics, 4P Pharma, Rubedo Life Sciences, Inc., Nobelpharma Co., Ltd., The Scripps Research Institute and others.
• Promising Scleroderma Pipeline Therapies such as Divozilimab, C-82 Topical Gel, 1%, Dasatinib, imatinib mesylate, Abatacept, Avenciguat (BI 685509), GSK2330811, Nintedanib, FT011 and others.

Stay ahead with the most recent pipeline outlook for Scleroderma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Scleroderma Treatment Drugs

Scleroderma Emerging Drugs Profile

• Inebilizumab: Mitsubishi Tanabe Pharma Corporation

Inebilizumab, also callled MEDI-551 is a humanized, anti-CD19 monoclonal antibody that binds to CD19, leading to antibody-dependent, cell-mediated cytotoxicity of B cells. CD19 is involved in B-cell signaling, intervening in the balance between humoral, antigen-induced response and tolerance induction. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Scleroderma.

• HZN-825: Amgen

HZN-825 (Fipaxalparant) is a molecule that blocks lysophosphatidic acid receptor 1 (LPAR1). It is being investigated for the treatment of diffuse cutaneous systemic sclerosis. It is a small molecule acting as a negative allosteric modulator of LPAR1. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Scleroderma.

• MT-7117: Mitsubishi Tanabe Pharma America Inc.

Dersimelagon (MT-7117), a novel synthetic, oral, selective melanocortin-1 receptor agonist, demonstrated disease-modifying effects in preclinical models of systemic sclerosis (SSc). MT-7117 reduces inflammation, vascular dysfunction, and fibrosis through its pleiotropic effects on inflammatory cells, endothelial cells, and fibroblastsis, and is as a potential therapeutic agent for the treatment of SSc. Currently, the drug is in the Phase II stage of development to treat Scleroderma.

• RO7303509: Genentech, Inc.

RG-6315 (RO-7303509) is under development for the treatment of inflammation, fibrosis and systemic sclerosis. The drug candidate is administered through subcutaneous or intravenous routes. It is a new molecular entity (NME). Currently, the drug is in the Phase I stage of development to treat Scleroderma.

• Soquelitinib: Corvus Pharmaceuticals

Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function.. Currently, the drug is in the Preclinical stage of development to treat Scleroderma.

The Scleroderma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Scleroderma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Scleroderma Treatment.
• Scleroderma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Scleroderma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Scleroderma market

Explore groundbreaking therapies and clinical trials in the Scleroderma Pipeline. Access DelveInsight’s detailed report now! @ New Scleroderma Drugs

Scleroderma Companies

AstraZeneca, Mitsubishi Tanabe Pharma Corporation, GlaxoSmithKline, Boehringer Ingelheim, Novartis Pharmaceuticals, Certa Therapeutics, Argenx, Cumberland Pharmaceuticals, Sanofi, Amgen, Genentech, Inc., Cabaletta Bio, Kyverna Therapeutics, ChemomAb Ltd., Corvus Pharmaceuticals, Quoin Pharmaceuticals Ltd., aTyr Pharma, APIE Therapeutics, 4P Pharma, Rubedo Life Sciences, Inc., Nobelpharma Co., Ltd., The Scripps Research Institute and others.

Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Scleroderma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Scleroderma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Scleroderma Market Drivers and Barriers

Scope of the Scleroderma Pipeline Report

• Coverage- Global
• Scleroderma Companies- AstraZeneca, Mitsubishi Tanabe Pharma Corporation, GlaxoSmithKline, Boehringer Ingelheim, Novartis Pharmaceuticals, Certa Therapeutics, Argenx, Cumberland Pharmaceuticals, Sanofi, Amgen, Genentech, Inc., Cabaletta Bio, Kyverna Therapeutics, ChemomAb Ltd., Corvus Pharmaceuticals, Quoin Pharmaceuticals Ltd., aTyr Pharma, APIE Therapeutics, 4P Pharma, Rubedo Life Sciences, Inc., Nobelpharma Co., Ltd., The Scripps Research Institute and others.
• Scleroderma Pipeline Therapies- Divozilimab, C-82 Topical Gel, 1%, Dasatinib, imatinib mesylate, Abatacept, Avenciguat (BI 685509), GSK2330811, Nintedanib, FT011 and others.
• Scleroderma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Scleroderma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Scleroderma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Scleroderma Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Scleroderma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Scleroderma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Inebilizumab: Mitsubishi Tanabe Pharma Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. HZN-825: Amgen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RO7303509: Genentech, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Soquelitinib: Corvus Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Scleroderma Key Companies
21. Scleroderma Key Products
22. Scleroderma- Unmet Needs
23. Scleroderma- Market Drivers and Barriers
24. Scleroderma- Future Perspectives and Conclusion
25. Scleroderma Analyst Views
26. Scleroderma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/scleroderma-pipeline-insight